(Also see "Philip Morris And Carlyle Go To Auction For Vectura" - Scrip, 9 August, 2021.)	The Takeover Panel is stepping in to oversee an auction process after two revised offers in recent days from rivals Philip Morris International Inc. and Carlyle upped the ante in the bidding war for the UK respiratory company Vectura Group plc.
(Also see "The Inside Story On How Bayer Swooped On NASDAQ-Bound Vividion" - Scrip, 5 August, 2021.)	It has taken just seven weeks from a cold call to completion and Bayer AG has got its hands on a prized asset in Vividion Therapeutics, Inc., which was on the verge of listing on the NASDAQ. The companies told Scrip how the deal was done.
(Also see "After Years Of Setbacks, Marinus Closes In On Rare Epilepsy Opportunity" - Scrip, 4 August, 2021.)	After multiple failed attempts to treat rare conditions, Marinus Pharmaceuticals, Inc. is on the cusp of success with ganaxolone in genetic epilepsy, and has secured a new European partner in Orion Corporation.
(Also see "Ipsen Targets External Innovation With Exicure Option In Rare Neurodegenerative Disorders" - Scrip, 3 August, 2021.)	France’s Ipsen SA has taken an exclusive option on two neurodegenerative disease programs at US biotech Exicure, Inc., whose oligonucleotide nanoparticles are taken up by many tissues, including the brain.
(Also see "Sanofi Goes All The Way In mRNA With Translate Bio Buy" - Scrip, 3 August, 2021.)	Taking full control of partner Translate Bio in a $3.2bn buyout means that Sanofi is the only big vaccine company with a wholly-owned mRNA platform in-house but observers say it is too early to declare that the Paris-headquartered group has bagged itself a bargain.
(Also see "Canadian Biotech Takes COVID-19 Nasal Spray To Asia Via Glenmark" - Scrip, 3 August, 2021.)	Glenmark Pharmaceuticals Limited hopes to launch SaNOtize Research and Development Corporation’s nitric oxide nasal spray for COVID-19 in India by the fourth quarter of 2021 post Phase III trials, as part of wider deal that covers other Asian markets.
(Also see "Lannett Adds To Respiratory Pipeline With Spiriva Rival" - Generics Bulletin, 3 August, 2021.)	Lannett Company, Inc. has added another respiratory generic to its development partnership with China’s Respirent, in the form of a rival to Boehringer Ingelheim’s tiotropium-based Spiriva Handihaler.
(Also see "Takeda Takes Alliance Route For Norovirus Vaccine" - Scrip, 30 July, 2021.)	Takeda again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.
(Also see "Ipsen Buys Into BAX Inhibitor, Targeting Certain Cancers" - Scrip, 28 July, 2021.)	Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics Inc. to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.
(Also see "BioXpress And Abzena Partner On Biosimilar Development" - Generics Bulletin, 28 July, 2021.)	BioXpress Therapeutics SA and Abzena plc, two service providers with expertise in biosimilar development, have partnered to support biosimilar development for third party customers.
(Also see "Amgen Builds Out Antibody Interests With $2.5bn Teneobio Buy" - Scrip, 28 July, 2021.)	Private California venture Teneobio, Inc. will bring additional expertise and novel platforms to acquisitive biotech giant Amgen, Inc. as it looks to expand its interests in bispecific and multispecific antibody technologies.
(Also see "AC Immune Beefs Up Neurodegenerative Pipeline With AFFiRiS Alpha-Synuclein Portfolio" - Scrip, 27 July, 2021.)	AC Immune SA is looking to AFFiRiS GmbH to help expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.
(Also see "Organon's First Move Post Spinout Is A Licensing Deal With ObsEva In Preterm Labor" - Scrip, 27 July, 2021.)	Organon will pay ObsEva SA $25m up front for worldwide commercialization rights to ebopiprant for acute preterm labor, which currently has no approved treatments in the US.
(Also see "Sun Strikes Deal For Clascoterone In US And Canada" - Generics Bulletin, 27 July, 2021.)	Sun Pharmaceutical Industries Ltd. has expanded its dermatology portfolio by entering into a partnership with Italy’s Cassiopea S.p.A. to market Winlevi (clascoterone) 1% cream in the US and Canada, and expects to make it available in the US in the fourth quarter of 2021.
(Also see "Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy" - Scrip, 22 July, 2021.)	Pfizer Inc. agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.
(Also see "Intas Picks Up Global Rights To Meiji And Dong-A’s Stelara Biosimilar" - Generics Bulletin, 21 July, 2021.)	Japan’s Meiji Seika Pharma Co., Ltd and Korea’s Dong-A Socio Holdings have struck an exclusive licensing deal with Intas Pharmaceuticals Ltd. for global rights to the pair’s DMB-3115 proposed ustekinumab biosimilar to Stelara.
(Also see "Stada Partners With Calliditas On Novel Budesonide Formulation" - Generics Bulletin, 21 July, 2021.)	STADA Arzneimittel AG has struck a licensing and commercialization deal with Calliditas Therapeutics AB worth more than $100m to partner on a novel oral formulation of budesonide to treat Immunoglobulin A Nephropathy in Europe.

Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal

More from Deals

More from Business